Cabozantinib

Science Daily: By boosting innate immunity, researchers eradicate aggressive prostate cancer in mice - Drug activates neutrophils instead of T cells, leading to cancer clearance

summary - Cabozantinib, an FDA-approved drug for patients with certain types of thyroid or kidney cancer, was able to eradicate invasive prostate cancers in mice by causing tumor cells to secrete factors that entice neutrophils -- the first-responders of the immune system -- to infiltrate the tumor. This novel approach, utilizing the innate immune system, produced near-complete clearance of invasive prostate cancers within 48 to 72 hours.